biostudies-literatureCreasy CANCIAdelson Medical Research FoundationNational Cancer InstitutesNCI NIH HHSNIH1911-1924https://www.ebi.ac.uk/biostudies/studies/S-EPMC9064946biostudies-literatureUnknown28(9)<h4>Purpose</h4>Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TIL) historically yields a 40%-50% response rate in metastatic melanoma. However, the determinants of outcome are largely unknown.<h4>Experimental design</h4>We investigated tumor-based genomic correlates of overall survival (OS), progression-free survival (PFS), and response to therapy by interrogating tumor samples initially collected to generate TIL infusion products.<h4>Results</h4>Whole-exome sequencing (WES) data from 64 samples indicated a positive correlation between neoantigen load and OS, but not PFS or response to therapy. RNA sequencing analysis of 34 samples showed that expression of PDE1C, RTKN2, and NGFR was enriched in responders who had improved PFS and OS. In contrast, the expression of ELFN1 wClinical cancer research : an official journal of the American Association for Cancer ResearchGenomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.PMC9064946P30CA016672P50 CA221703#R01CA184845P30 CA016672R01 CA184845#04-7023433P50CA221703Haymaker CZhang JWong MKYee CTomczak KGarraway LBeroukhim RTorres-Cabala CAHoon DSBStewart CDiab ACreasy CAPatel SPAmaria RNForget MAKarpinets TBernatchez CPilon-Thomas STawbi HMeng YJSarnaik AAMule JJHwu PDavies MAMcQuade JGlitza ICBustos MfalseGenomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.<h4>Purpose</h4>Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TIL) historically yields a 40%-50% response rate in metastatic melanoma. However, the determinants of outcome are largely unknown.<h4>Experimental design</h4>We investigated tumor-based genomic correlates of overall survival (OS), progression-free survival (PFS), and response to therapy by interrogating tumor samples initially collected to generate TIL infusion products.<h4>Results</h4>Whole-exome sequencing (WES) data from 64 samples indicated a positive correlation between neoantigen load and OS, but not PFS or response to therapy. RNA sequencing analysis of 34 samples showed that expression of PDE1C, RTKN2, and NGFR was enriched in responders who had improved PFS and OS. In contrast, the expression of ELFN1 w2022-01-01T00:00:00Z2022 May2026-05-09T19:29:54.477Z2025-04-19T22:46:48.897ZS-EPMC90649463519082310.1158/1078-0432.CCR-21-106010.1158/1078-0432.ccr-21-1060